HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fernando de Mora Selected Research

butaprost

7/2020In Vitro and In Vivo Validation of EP2-Receptor Agonism to Selectively Achieve Inhibition of Mast Cell Activity.
12/2012E-prostanoid 2 receptors dampen mast cell degranulation via cAMP/PKA-mediated suppression of IgE-dependent signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Fernando de Mora Research Topics

Disease

7Asthma (Bronchial Asthma)
10/2021 - 11/2008
4Inflammation (Inflammations)
01/2015 - 11/2008
2Hypersensitivity (Allergy)
07/2020 - 12/2012
2Pneumonia (Pneumonitis)
04/2013 - 10/2009
2Respiratory Hypersensitivity
04/2009 - 01/2009
1Immediate Hypersensitivity
12/2012
1Eosinophilia
01/2009
1Mastocytoma
05/2002

Drug/Important Bio-Agent (IBA)

4Dinoprostone (PGE2)FDA Link
10/2021 - 10/2009
3ProstaglandinsIBA
01/2015 - 11/2008
3Methacholine Chloride (Methacholine)FDA Link
04/2009 - 11/2008
2butaprostIBA
07/2020 - 12/2012
2Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
01/2015 - 11/2008
2Prostaglandins EIBA
12/2012 - 01/2009
2sulprostoneIBA
10/2009 - 01/2009
2AllergensIBA
10/2009 - 01/2009
2CytokinesIBA
01/2009 - 05/2002
1Bronchodilator Agents (Bronchodilators)IBA
01/2015
1Biological ProductsIBA
01/2015
1Interleukin-4 (Interleukin 4)IBA
04/2013
1Messenger RNA (mRNA)IBA
10/2009
1rofecoxib (Vioxx)FDA Link
04/2009
1OvalbuminIBA
04/2009
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
11/2008
1Antisense OligonucleotidesIBA
11/2008
1OligonucleotidesIBA
11/2008
1IgE Receptors (Fc epsilon RI)IBA
05/2002
1Immunoglobulin E (IgE)IBA
05/2002
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
05/2002